Efficacy and safety of paliperidone palmitate 6-month versus paliperidone palmitate 3-month long-acting injectable in european patients with schizophrenia: a post hoc analysis of a global phase-3 double-blind randomized non-inferiority study
Fecha de publicación:
2023
Versión del editor:
Citación:
Neuropsychiatric Disease and Treatment, 19, p. 895-906 (2023); doi:10.2147/NDT.S400342
Descripción física:
p. 895-906